Buy Veracyte on Prosigna and TrueMRD Momentum; Patient, Growth-Oriented Long Trade
Veracyte's focus on higher-margin oncology products - notably Prosigna and the emerging TrueMRD platform - creates a plausible growth runway. Fundamentals show solid free cash flow and a manageable market cap; technicals are mixed, offering a tactical entry near $47.22. This trade idea sets an entry at $47.22, a stop at $42.00, and a target at $62.…